氟巴尼酯 | 847-20-1

• 物质功能分类: 原料药 - 神经系统用药 - 抗抑郁、躁狂药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氟巴尼酯
• 英文名称: Flubanilate Hydrochloride
• 英文别名: flubanilate；ethyl N-[2-(dimethylamino)ethyl]-N-[3-(trifluoromethyl)phenyl]carbamate
• CAS: 847-20-1
• 化学式: C₁₄H₁₉F₃N₂O₂
• 分子量: 304.312
• InChiKey: NBODAQXRWMHEBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Ascending-dose dosage form
  申请人：ALZA CORPORATION

  公开号：EP1782798A2

  公开（公告）日：2007-05-09

  A dosage form and a method are disclosed for delivering to a human patient a drug in an ascending amount over time. In particular, the invention provides a dosage form having a length greater than its width, the dosage form comprising: (a) a first layer comprising 10 ng to 700 mg of a drug selected from methylphenidate or a pharmaceutically acceptable salt thereof; (b) a second layer comprising 80% to 95% of a hydrophilic-expandable polymer; (c) a wall comprising a semipermeable composition that surrounds the first and second layer; (d) an exit in the wall communicating with the first layer for delivering the drug; and wherein the dosage form when in operation administers the drug in an ascending rate over time.

  本发明公开了一种剂型和一种方法，用于向人类患者递送随时间递增的药物。特别是，本发明提供了一种长度大于宽度的剂型，该剂型包括 (a) 第一层，包含 10 毫微克至 700 毫克选自哌醋甲酯或其药学上可接受的盐的药物； (b) 第二层，包括 80%至 95%的亲水性可膨胀聚合物； (c) 包含半透性成分的壁，环绕第一层和第二层； (d) 壁中与第一层相通的出口，用于递送药物；以及其中的剂型在使用时以随时间递增的速率递送药物。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0174342A1

  公开（公告）日：1986-03-19